SVF
Level D· Preclinical EvidenceAnimal Study

Insulin-Like Growth Factor 1 in Exosomes Derived from Adipose-Derived Stem Cells Promotes Tendon-Bone Healing in Rotator Cuff Injuries.

Qi W., Jin Y., Shan H., Lu Y., Wang F.

Animal Study on Tendon Injury, Rotator Cuff, Chronic Wound, Chronic Inflammation, published in Front Biosci (Landmark Ed) (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Front Biosci (Landmark Ed) (2026)
Country
Singapore
Reported sample size
—
PMID
41761976
DOI
10.31083/FBL47168

Abstract (original English)

Rotator cuff injuries are common musculoskeletal disorders and are frequently complicated by impaired tendon-bone healing and high re-tear rates after surgical repair. Exosomes derived from adipose-derived stem cells (ADSCs) have shown regenerative potential through paracrine mechanisms; however, the role of exosomal insulin-like growth factor 1 (IGF1) in tendon-bone healing remains unclear. Exosomes were isolated from rat ADSCs with or without lentiviral knockdown of IGF1. A rat supraspinatus tendon tear and repair model was established, and 200 μg of exosomes was administered systemically post-surgery. Tendon-bone healing was evaluated at 8 weeks post-operation using histological, immunohistochemical, and micro-computed tomography analyses. Early molecular responses were assessed at 1-week post-surgery by Western blot and RT-qPCR. Angiogenic markers (vascular endothelial growth factor (VEGF), CD31, α-SMA), inflammatory cytokines (interleukin (IL)-1β, IL-18), pyroptosis-related proteins (gasdermin D N-terminal fragment (GSDMD-N)), and NLRP3 inflammasome components were examined. ADSC-derived exosomes significantly enhanced bone mineral density, fibrocartilage formation, vascularization, and biomechanical strength at the tendon-bone interface. These effects were accompanied by reduced inflammatory cytokine expression, inhibition of pyroptosis, and suppression of NLRP3 inflammas

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsExosomesInsulin-Like Growth Factor IRotator Cuff InjuriesRatsWound HealingMaleStem CellsRats, Sprague-DawleyAdipose Tissue
Face & SkinShoulderSystemic / IVTendon InjuryRotator CuffChronic WoundChronic Inflammation
View on PubMedDOI

Related research